Anzeige
Mehr »
Login
Dienstag, 07.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Warum der Warren Buffett des Bergbaus alles auf diese Aktie setzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
235 Leser
Artikel bewerten:
(1)

TATAA Biocenter goes live with a modern, fully-automated LIMS - a big day for their state-of-the-art laboratory in Gothenburg.

Finanznachrichten News

GOTHENBURG, Sweden, Nov. 22, 2022 /PRNewswire/ -- It's been over 12 months in the making and TATAA Biocenter has now gone live with its Laboratory Information Management System (LIMS) from Benchling. Integrating processes, samples, instruments, and informatics into one automated and unified platform.

Effectively managing sequencing and PCR data can be challenging, with issues in data security and sample management and potential mistakes caused by human error.

A modern LIMS solution allows you to connect everything in the laboratory so you can record and trace all that you do to an individual sample. Every process, every measurement.

"LIMS is a way to bulletproof your processes. A customer will be able to follow the whole process of a sample, every concentration, how many PCR cycles. It makes it easy to trouble-shoot issues or biases with a specific sample, since you have all the data collected and stored, and traceable. That can't be deleted." says Sofia Adolfsson, Head of Bioinformatics, TATAA Biocenter.

This LIMS solution seamlessly integrates TATAA's key laboratory instruments, including the NGS star Library Prep and Illumina sequencers, improving quality control while increasing throughput and productivity, for NGS and dPCR analysis.

TATAA Biocenter selected Benchling as its LIMS platform for its end-to-end solution and robust compliance capabilities. The R&D Cloud provides a centralised source of truth, so users don't need to capture and manage data in multiple places and systems. This will also help with future compliance requirements, such as 21 CFR Part 11 compliance/GLP.

TATAA Biocenter and Benchling collaborated closely throughout the entire project, working side-by side, going through each process, in a detailed way, to make sure everything in the laboratory was documented.

"During this integration, we considered ourselves as an integral and embedded part of the team at TATAA Biocenter, finding the right approach to serve them at every step of their journey," said Abdel Batel, Head of Professional Services EMEA, Benchling. "We know that with Benchling, TATAA Biocenter laboratory is equipped with the most trusted, high-quality tools that empower their customers to increase productivity and shorten delivery times with R&D."

With Benchling's LIMS, TATAA ensures the capture of high-quality, structured and unstructured data for customers, which is critical to scientists' ability to ask and answer new questions. It is purpose built for science - capturing DNA, RNA, proteins, and more - and structures the data in a way that is accessible, interoperable, and reusable.

This focus on data quality and structure helps TATAA and its customers manage their intellectual property more effectively, making it easier for R&D teams to maintain IP security and streamline the process of IP transfer that occurs when organisations combine or partner.

The LIMS has been set up specifically for the needs of TATAA Biocenter and will stand out to customers as a critical competitive differentiator. A tailored and unique system bringing many benefits to TATAA's scientists and customers.

CONTACT:

Martin Cooke
TATAA Biocenter
Marketing & Comms Specialist
martin.cooke@tataa.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/tataa-biocenter-goes-live-with-a-modern-fully-automated-lims--a-big-day-for-their-state-of-the-art-laboratory-in-gothenburg-301685003.html

© 2022 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.